Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338
Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Armer, Nathan C. ... - - Support Care Cancer - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Ostby, Pamela L. ... - - JAMA Surg - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance) Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials Bernhard, Jürg , Luo, Weixiu , Ribi, Karin , Colleoni, Marco ... - - Lancet Oncol. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials Berry, Donald A. , Ueno, Naoto T. , Johnson, Marcella M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - INT-0163
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993 Manuscript - Primary Endpoint - Primary Analysis - Breast - C8743
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) Boughey, Judy C. , Ballman, Karla V. , Hunt, Kelly K. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Le-Petross, Huong T. ... - - Ann. Surg. - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z1071
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071 Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda ... - SABCS - Cancer Res. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial Boughey, Judy C. , McCall, Linda M. , Ballman, Karla V. ... - - Ann. Surg. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance). Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - Ann. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - JAMA - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance) Burstein, Harold J. , Cirrincione, Constance T. , Barry, William T. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041) Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - - JAMA Oncol - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial Buzdar, Aman U , Suman, Vera J , Meric-Bernstam, Funda ... - - Lancet Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Campbell, Jeffrey I. , Yau, Christina , Krass, Polina , Moore, Dan ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib Carey, Lisa A. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40601
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - C40601
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial Cheng, H , Ballman, K , Vassilakopoulou, M , Dueck, A C ... - - Br. J. Cancer - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance) Chua, Katherina C. , Ho, Carol , Mushiroda, Tasei , Jiang, Chen ... - ASCPT - Clinical Pharmacology & Therapeutics - 2018 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-40101 , CALGB-40502
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 Chumsri, Saranya , Li, Zhuo , Serie, Daniel J. ... - - J. Clin. Oncol - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831 , NSABP B-31
Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials Chumsri, Saranya , Serie, Daniel J. , Li, Zhuo ... - - Clin. Cancer Res. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831 , NSABP B-31
Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer. Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52
Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52 Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52
ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Crozier, J. A. , Moreno-Aspitia, A. , Ballman, K. V. , Dueck, A. C. ... - - Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy Crozier, Jennifer A. , Advani, Pooja P. , LaPlant, Betsy ... - - Clin. Breast Cancer - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0436
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Cureton, Elizabeth L. , Yau, Christina , Alvarado, Michael D. ... - - Ann. Surg. Oncol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William T. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D
Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer) Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N1031
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial Eiger, D. , Ponde, N. F. , Agbor-Tarh, D. , Moreno-Aspitia, Alvaro ... - ESMO Breast - Annals of Oncology - 2019 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - N063D , ALTTO
ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer Ellis, M. J. , Buzdar, A. U. , Unzeitig, G. W. , Esserman, L. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10% Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy ... - - J. Clin. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy , Lin, Li ... - - J. Clin. Oncol. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601
Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial Fleming, Gini F , Francis, Prudence A , Láng, István ... - SABCS - Ann. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Francis, P. A. , Pagani, O. , Fleming, G. F. , Walley, B. A. ... - - N. Engl. J. Med. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT) , IBCSG-25-02 (TEXT) , S0002
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer Francis, Prudence A. , Regan, Meredith M. , Fleming, Gini F. ... - - N. Engl. J. Med. - 2015 Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer Francis, Prue , Fleming, Gini , Regan, Meredith , Pagani, Olivia ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance] Gajra, Ajeet , McCall, Linda , Muss, Hyman B. , Cohen, Harvey J. ... - SABCS - Cancer Res. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer Garber, Judy E. , Halabi, Susan , Tolaney, Sara M. , Kaplan, Ellen ... - - J Natl Cancer Inst - 2010 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9872
Local and Regional Control in Breast Cancer after Sentinel Node Biopsy without Axillary Lymph Node Dissection: Results from a Randomized Trial Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. W. ... - ASA - American Surgical Association 130th Annual Meeting - 2010 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1 - 2 N0 M0 breast Cancer who have a positive sentinel node Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis Giuliano, Armando E. , Ballman, Karla V. , McCall, Linda ... - - JAMA - 2017 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial Giuliano, Armando E. , Ballman, Karla , McCall, Linda ... - - Ann. Surg. - 2016 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Association of occult metastases in sentinel lymph nodes and bone marrow with survival of women with early-stage invasive breast cancer Giuliano, Armando E. , Hawes, Debra , Ballman, Karla V. ... - - JAMA - 2011 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Ten-Year Survival Results of ACOSOG Z0011 (Alliance) Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - - JAMA - 2011 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) Z0011 Randomized Trial Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - ASA - - 2016 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - - Ann. Surg. - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance). Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald A. ... - ASA - - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603
Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance) Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603
Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates Golshan, Mehra , Cirrincione, Constance T. , Sikov, William M. ... - - Ann. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) Golshan, Mehra , Cirrincione, Constance T. , Sikov, William M. ... - - Breast Cancer Res. Treat. - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601
Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study Grant, Clive S. , Ingle, James N. , Suman, Vera J. ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Breast - N9431
Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: Results from ACOSOG 1071 Clinical Trial Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Radiation use and field design in women with node positive breast cancer treated with preoperative systemic therapy and breast surgery including axillary dissection on a prospective clinical trial ACOSOG Z1071 [Alliance] Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - ASTRO - Int J Radiation Biol Physics - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: Results from ACOSOG Z1071 (Alliance) Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND); results from ACOSOG Z1071 (Alliance) Haffty, Bruce , Ballman, Karla , Hunt, Kelly , McCall, Linda ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in HER2 positive breast cancer Haluska, P. , Reinholz, M. M. , Dueck, A. C. , Linden, H. M. ... - - J. Clin. Oncol. - 2010 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - N0733
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance). Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Breast - N0733
Impact of Adjuvant Trastuzumab on Local Regional Recurrence; Data from the NCCTG N9831 study. Halyard, M. Y. , Dueck, A. C. , Pisansky, T. M. , Mclaughlin, S. A. ... - SABCS - Cancer Res. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Changes in left ventricular function after radiation therapy and trastuzumab: analysis of North Central Cancer Treatment Group Phase III Trial N9831. Halyard, M. , Pisansky, T. M. , Pierce, L. J. , Solin, L. J. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831 Halyard, Michele Y. , Pisansky, Thomas M. , Dueck, Amylou C. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Henderson, I Craig , Berry, Donald A , Demetri, George D ... - - J. Clin. Oncol. - 2003 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9344
Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without+/- lapatinib (L) for HER2-positive breast cancer Hoadley, Katherine A. , Barry, William T. , Pitcher, Brandelyn N. ... - SABCS - Cancer Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy Hobday, T. J. , Stella, P. J. , Fitch, T. R. , Jaslowski, A. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0436
A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane. Hobday, T. , Rowland, K., Jr , Dueck, A. , Northfelt, D. , Lingle, W. ... - ASCO Breast - Breast Cancer Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer Hughes, K. S. , Schnaper, L. , Cirrincione, C. T. , Berry, D. A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-9343
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343 Hughes, Kevin S. , Schnaper, Lauren A. , Bellon, Jennifer R. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-9343
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. Hughes, Kevin S , Schnaper, Lauren A , Berry, Donald ... - - N. Engl. J. Med. - 2004 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9343
Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. Hume, C. Bueno , Moreno-Aspitia, A. , Hillman, D. , Chen, B. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N083E
A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071 Hunt, K. , Le-Petross, H. T. , Suman, V. , Haffty, B. G. ... - - J. Clin. Oncol. - 2010 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - ACOSOG-Z1071
Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial Hunt, Kelly K. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC) Hunt, Kelly K. , Suman, Vera J. , Meric-Bernstam, Funda ... - SSO - Ann Surg Oncol - 2019 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) (Alliance) CALGB 40903 Hwang, E. Shelley , Duong, Stephanie , Bedrosian, Isabelle ... - SABCS - Cancer Res - 2017 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40903
MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657 Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007
Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657 Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - - Cancer Res. - 2009 Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007
MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007 Hylton, N. M. , Blume, J. , Gastonis, C. , Gomez, R. , Bernreuter, W. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACRIN-6657 , CALGB-150007
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL Hylton, Nola M. , Blume, Jeffrey D. , Bernreuter, Wanda K. ... - - Radiology - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-150007
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL Hylton, Nola M. , Gatsonis, Constantine A. , Rosen, Mark A. ... - - Radiology - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603 Iglesia, Michael D. , Vincent, Benjamin G. , Serody, Jonathan S. ... - SABCS - Cancer Res. - 2014 Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603
Radiation field design on the ACOSOG Z0011 trial Jagsi, R. , Ballman, K. , Chadha, M. , Moni, J. , Laurie, F. ... - SABCS - Cancer Res. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial Jagsi, Reshma , Chadha, Manjeet , Moni, Janaki , Ballman, Karla ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Nomogram-Based Estimate of Axillary Nodal Involvement in ACOSOG Z0011 (Alliance): Validation and Association with Radiation Protocol Variations and Outcomes Katz, Matthew S. , McCall, Linda , Ballman, Karla , Haffty, Bruce G. ... - ASTRO - Int J Radiat Oncol Biol Phys - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Cancer Surveillance Behaviors and Psychosocial Factors Among Long-Term Survivors of Breast Cancer Katz, Mira L. , Donohue, Kathleen A. , Alfano, Catherine M. ... - - Cancer - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-79804
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) Kimmick, G. G. , Cirrincione, C. , Duggan, D. B. , Bhalla, K. ... - - Breast Cancer Res. Treat. - 2009 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - C8944
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831 Knutson, K. L. , Perez, E. A. , Ballman, K. , Erskine, C. L. , Fox, N. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain Knutson, Keith L. , Clynes, Raphael , Shreeder, Barath ... - - Cancer Res. - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52 , N0938
Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer Knutson, Keith L. , Clynes, Raphael , Yeramian, Patrick ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52 , N0938
Quality of life of early stage breast cancer patients 65 years old or older randomized to standard chemotherapy or capecitabine (CALGB 49907) Kornblith, A. B. , Archer, L. E. , Lan, L. , Kimmick, G. G. ... - - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907
Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab Krop, Ian E. , Hillman, David , Polley, Mei , Tanioka, Maki ... - SABCS - Cancer Res - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer Kutteh, L.A.. , Hobday, T. J. , Jaffe, A. S. , Laplant, B. R. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants Lamont, E. B. , Herndon, J. E. 2nd , Weeks, J. C. , Henderson, I. C. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Comprehensive Analysis - Breast - CALGB-70101 , CALGB-9730 , INT-0148
Central review versus local review of axillary ultrasound prior to and after neoadjuvant chemotherapy: Results from the American College of Surgeons Oncology Group Z1071 trial (Alliance) Le-Petross, H. Carisa , McCall, Linda M. , Hunt, Kelly K. ... - ARRS - - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071) Le-Petross, H. T. , Mccall, L. , Hunt, K. , Mittendorf, E. A. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) Le-Petross, Huong T. , McCall, Linda M. , Hunt, Kelly K. ... - - AJR Am J Roentgenol - 2018 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL Li, Wen , Arasu, Vignesh , Newitt, David C. , Jones, Ella F. ... - - Tomography - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACRIN 6657 , CALGB-150007
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 Lichtman, S. M. , Hurria, A. , Cirrincione, C. T. , Seidman, A. D. ... - - Ann. Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-9342 , CALGB-9840
The Breast Cancer Weight Loss (BWEL) Trial: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer (Alliance A011401) Ligibel, Jennifer A. , Barry, William T. , Alfano, Catherine ... - ASCO - J Clin Oncol - 2018 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011401
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design Ligibel, Jennifer A. , Barry, William T. , Alfano, Catherine ... - - NPJ Breast Cancer - 2017 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011401
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance) Ligibel, Jennifer A. , Cirrincione, Constance T. , Liu, Minetta ... - - J. Natl. Cancer Inst - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - C9741 , CALGB-40902
Physical Activity, Weight and Outcomes in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from CALGB 40502 (Alliance) Ligibel, LJ , Heubner, JA , Rugo, HS , Burstein, H , Toppmeyer, DL ... - SABCS - Cancer Res - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40502
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) Lin, Cheryl , Buxton, Meredith Becker , Moore, Dan , Krontiras, Helen ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007 , CALGB-150012
Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial Liu, M.C. , Rack, B. , Dueck, A.C. , Hillman, D.W. , Campion, M.B. ... - SABCS - Cancer Res. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D
Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel Liu, Minetta C. , Demetri, George D. , Berry, Donald A. ... - - Cancer Treat Rev - 2008 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - C9141
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. Lucci, Anthony , McCall, Linda Mackie , Beitsch, Peter D ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study Ma, Cynthia X. , Suman, Vera , Leitch, A. Marilyn , Sanati, Souzan ... - SABCS - Cancer Res. - 2015 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011106
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082 Marks, L. B. , Cirrincione, C. , Fitzgerald, T. J. , Laurie, F. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-9082
Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Martin, Miguel , Loibl, Sibylle , Hyslop, Terry ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40503
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Martín, M , Loibl, S , Hyslop, T , De la Haba-Rodríguez, J , Aktas, B ... - - Eur. J. Cancer - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40503
Concordance of HER2 Central Assessment by Two International Central Laboratories: a ring study within the framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708. McCullough, AE , Dell'Orto, P , Reinholz, MM , Gelber, RD , Dueck, AC ... - - Cancer Res. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063DSS4
100% Concordance between IHC and FISH HER2 Testing Cannot Be Achieved Using N9831 Cohort Mccullough, A. E. , Chen, B. , Hillman, D. W. , Tenner, K. S. ... - USCAP - Lab Invest - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831
Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important Mittendorf, E. , Ballman, K. , Mccall, L. , Hansen, N. , Lucci, A. ... - ASCO - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer Mittendorf, Elizabeth A. , Ballman, Karla V. , McCall, Linda M. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Serum Biomarker Analysis in a Phase II Study of Irinotecan in Refractory Metastatic Breast Cancer Moreno-Aspitia, A. , Anderson, S. , Reinholz, M. , Dueck, A. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-96-32-55
Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2 + BC): Results from the NCCTG adjuvant intergroup trial N9831 Moreno-Aspitia, A. , Dueck, A. , Lingle, W. , Kutteh, L. , Tenner, K. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial Moreno-Aspitia, A. , Dueck, A. , Patel, T. , Hillman, D. , Tenner, K. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N9831
Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831 Moreno-Aspitia, A. , Hillman, D. W. , Dueck, A. C. , Carney, W. P. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy with or without trastuzumab: Results from the NCCTG adjuvant trial N9831 Moreno-Aspitia, A. , Hillman, D. W. , Dyar, S. H. , Tenner, K. S. ... - - Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC) Moreno-Aspitia, A. , Liu, H. , Hillman, D. , Rowland, K. M. Jr ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - N0937
N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC) Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Breast - N0937
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer Moreno-Aspitia, Alvaro , Holmes, Eileen , Jackisch, Christian ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D
Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 Moreno-Aspitia, Alvaro , Morton, Roscoe F. , Hillman, David W. ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0336
MRI phenotype and tumor subtype affect breast conservation eligibility and MRI accuracy in the I-SPY 1 trial Mukhtar, R. A. , Hylton, N. M. ... - - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Mukhtar, Rita A. , Yau, Christina , Rosen, Mark , Tandon, Vickram J. ... - - Ann. Surg. Oncol - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Standard chemotherapy vs capecitabine for older women with early-stage breast cancer: Long-term results of CALGB 49907 (Alliance) Muss, Hyman B. , Berry, Donald A. , Cirrincione, Constance T. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-49907
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer Muss, Hyman B. , Berry, Donald A. , Cirrincione, Constance T. ... - - N Engl J Med - 2009 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-49907
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial Muss, Hyman B. , Polley, Mei-Yin C. , Berry, Donald A. , Liu, Heshan ... - - J. Clin. Oncol - 2019 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-49907
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. Muss, Hyman B , Berry, Donald A , Cirrincione, Constance ... - - J. Clin. Oncol. - 2007 Manuscript - Primary Endpoint - Comprehensive Analysis - Breast - C8541 , C9741
Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735 Northfelt, D. W. , Dueck, A. C. , Flynn, T. P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary Endpoint - Primary Analysis - Breast - N0735
Phase II trial of polyglutamated paclitaxel (PPX) with capecitabine for metastatic breast cancer Northfelt, D. , Allred, J. , Liu, H. , Hobday, T. , Rodacker, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - N0437
Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer Northfelt, DW , Allred, JB , Liu, H , Hobday, TJ , Rodacker, MW ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0437
Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 Norton, Nadine , Olson, Rebecca M. , Pegram, Mark , Tenner, Kathleen ... - - Cancer Immunol Res - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance) Ollila, D. , Berry, D. , Cirrincione, C. , Carey, L. , Amos, K. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - C40601
Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative) Ollila, David W , Cirrincione, Constance T , Berry, Donald A ... - - J. Am. Coll. Surg. - 2017 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-40601 , CALGB-40603
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL Olshen, Adam , Wolf, Denise , Jones, Ella F. , Newitt, David ... - - J Med Imaging (Bellingham) - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-150007
ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor positive breast cancer Olson, J. A. Jr , Babiera, G. V. , Unzeitig, G. , Marcom, P. K. ... - ASCO Breast - Breast Cancer Symposium - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. Olson, John A , McCall, Linda M , Beitsch, Peter , Whitworth, Pat W ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - ACOSOG-Z0010 , ACOSOG-Z0011
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials Pagani, Olivia , Regan, Meredith M. , Fleming, Gini F. ... - SABCS - Cancer Res - 2018 Abstract - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT) , IBCSG-25-02 (TEXT)
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. Parnes, H L , Cirrincione, C , Aisner, J , Berry, D A , Allen, S L ... - - J. Clin. Oncol. - 2003 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9140
Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-based therapy. Pascual, Tomás , Tanioka, Maki , Dieci, M.Vittoria , Pernas, Sonia ... - SABCS - Cancer Res - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
Analysis of the associations of FC gamma receptor polymorphisms (FCGR3A, FCGR2A, and FCGR2B) with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831 Pegram, Mark , Norton, Nadine , Tenner, Kathleen , Ballman, Karla L. ... - AACR Adv Br - Mol Cancer Res - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer. Perez, E. A. , Dueck, A. C. , Press, M. F. , Chen, B. , Jenkins, R. B. ... - SABCS - Cancer Res. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer Perez, E. A. , Hillman, D. W. , Dentchev, T. , Le-Lindqwister, N. A. ... - - Ann Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0432
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) Perez, E. A. , Press, M. F. , Dueck, A. C. , Jenkins, R. B. , Kim, C. ... - - Breast Cancer Res. Treat. - 2013 Manuscript - Secondary Endpoint - Comprehensive Analysis - Breast - N9831
Do the ASCO/CAP 2007 HER2 testing guidelines improve prediction of benefit to adjuvant trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant trial. Perez, E. A. , Reinholz, M. M. , Dueck, A. C. , Tenner, K. S. ... - - Cancer Res. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with or without trastuzumab (H) in patients (pts) with HER2-positive breast cancer Perez, E. A. , Romond, E. H. , Suman, V. J. , Jeong, J. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - N9831
The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831 Perez, E. , Butler, S. , Dueck, A. , Baehner, F. , Jamshidian, F. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831 Perez, E. , Dueck, A. L. , Reinholz, M. M. , Chen, B. , Geiger, X. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study Perez, E. , Eckel-Passow, J. , Ballman, K. , Anderson, S. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
c-MYC (MYC) Amplification and Correlation With Patient Outcome in Early Stage HER2 + Breast Cancer (BC) From the NCCTG Adjuvant Intergroup Trial N9831 Perez, E. , Reinholz, M. , Dueck, A. , Wiktor, A. , Lingle, W. ... - - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 Perez, Edith A. , Baehner, Frederick L. , Butler, Steven M. ... - - Breast Cancer Res - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N9831
Stromal tumor infiltrating lymphocytes: In the Alliance N9831 trial STILS are prognostic of chemotherapy benefit but not predictive of trastuzumab benefit Perez, Edith A. , Ballman, Karla V. , Anderson, S. Keith ... - SABCS - Cancer Res. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial Perez, Edith A. , Ballman, Karla V. , Mashadi-Hossein, Afshin ... - - J. Natl. Cancer Inst - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Intrinsic subtype and therapeutic response among early stage HER2-positive breast tumors from the North Central Cancer Treatment Group (Alliance) N9831 trial Perez, Edith A. , Ballman, Karla V. , Mashadi-Hossein, Afshin ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer Perez, Edith A. , Ballman, Karla V. , Tenner, Kathy S. ... - - JAMA Oncol - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J Natl Cancer Inst - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D
C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial Perez, Edith A. , Jenkins, Robert B. , Dueck, Amylou C. ... - - J Clin Oncol - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial Perez, Edith A. , Reinholz, Monica M. , Hillman, David W. ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 Perez, Edith A. , Romond, Edward H. , Suman, Vera J. ... - - J Clin Oncol - 2011 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Perez, Edith A. , Romond, Edward H. , Suman, Vera J. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Comprehensive Analysis - Breast - N9831
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer Perez, Edith A. , Suman, Vera J. , Davidson, Nancy E. ... - - J Clin Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - Breast - N9831
Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial Perez, Edith A. , Thompson, E. Aubrey , Ballman, Karla V. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. Peters, William P , Rosner, Gary L , Vredenburgh, James J ... - - J. Clin. Oncol. - 2005 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9082
Adjuvant ovarian function suppression and cognitive function in women with breast cancer Phillips, Kelly-Anne , Regan, Meredith M , Ribi, Karin ... - - Br. J. Cancer - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Piccart-Gebhart, Martine J. , Holmes, Andrew Peter , Baselga, Jose ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Breast - N063D
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial Piccart-Gebhart, Martine , Holmes, Eileen , Baselga, José ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - N063D
Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapic trial Pockaj, B. A. , Dueck, A. , Tenner, K. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Effect of Docetaxel and Carboplatin on VEGF, PGE2, and Immune cells in Patients With Stage II or III Breast Cancer Pockaj, B. , Tinder, T. , Klosterman, C. , Allred, J. , Roy, V. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - N0338
Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B Polite, Blase N. , Cirrincione, Constance , Fleming, Gini F. ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-40501 , CALGB-9342 , CALGB-9840
Tolerability and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients Ponde, Noam Falbel , Agbor-Tarh, Dominique , Lago, Lissandra Dal ... - ASCO - JCO - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D
Predicting response and survival in chemotherapy-treated triple-negative breast cancer Prat, A , Lluch, A , Albanell, J , Barry, W T , Fan, C , Chacón, J I ... - - Br. J. Cancer - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-159905 , C9741
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT Regan, M. M. , Walley, B. A. , Francis, P. A. , Fleming, G. F. ... - - Ann. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials Regan, Meredith M. , Francis, Prudence A. , Pagani, Olivia ... - - J. Clin. Oncol - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials Regan, Meredith M. , Pagani, Olivia , Fleming, Gini F. ... - - Breast - 2013 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials Regan, Meredith M. , Pagani, Olivia , Francis, Prudence A. ... - - Breast Cancer Res. Treat. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Effect of IGFIR protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial Reinholz, M. M. , Dueck, A. L. , Chen, B. , Geiger, X. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
MYC protein expression and copy number anomalies in early-stage HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831. Reinholz, M. M. , Geiger, X. , Dueck, A. C. , Wiktor, A. E. ... - ASCO MM - Molecular Markers in Cancer - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831
Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437 Reinholz, M. , Kitzmann, K. , Hobday, T. , Northfelt, D. , Laplant, B. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - N0436 , N0437
Circulating tumor cells in North Central Cancer Treatment Group breast clinical trials Reinholz, M. , Kitzmann, K. , Tenner, K. , Hillman, D. , Hobday, T. ... - ISMRC - 7th International Symposium on Minimal Residual Cancer - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - N0234 , N0336 , N0338 , N0436 , N0437
c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831 Reinholz, MM , Dueck, AC , Wiktor, AE , Lingle, WL , Jenkins, RB ... - - Cancer Res. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831 Reinholz, Monica M. , Chen, Beiyun , Dueck, Amylou C. ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N9831
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437 Reinholz, Monica M. , Kitzmann, Kathleen A. , Tenner, Kathleen ... - - Clin. Cancer Res. - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0336 , N0234 , N0338 , N0436 , N0437
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial Ribi, Karin , Luo, Weixiu , Bernhard, Jürg , Francis, Prudence A. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy Ribi, Karin , Luo, Weixiu , Burstein, Harold J. ... - SABCS - Cancer Research - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840 Rimm, D. L. , Broadwater, G. , Friedman, P. N. , Berry, D. A. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-9840
Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 Romond, E. H. , Suman, V. J. , Jeong, J.-H. , Sledge, G. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Comprehensive Analysis - Breast - N9831
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. Romond, Edward H , Perez, Edith A , Bryant, John , Suman, Vera J ... - - N. Engl. J. Med. - 2005 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: An initial report from ACOSOG Z11102 (Alliance) trial Rosenkranz, Kari M. , Ballman, Karla , McCall, Linda ... - - Ann. Surg. Oncol. - 2018 Manuscript - Secondary Endpoint - Preliminary Analysis - Breast - Z11102
The feasibility of breast conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) trial Rosenkranz, Kari , McCall, Linda , Ballman, Karla ... - ASBrS - Ann. Surg. Oncol. - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - Z11102
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531) Roy, V. , LaPlant, B. R. , Gross, G. G. , Bane, C. L. ... - - Ann Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-0531
NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC) Roy, V. , Laplant, B. , Gross, G. , Palmieri, F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Breast - N0531
N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer Roy, V. , Pockaj, B. , Northfelt, D. , Allred, J. , Liu, H. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - N0338
A Phase II trial of docetaxel and carboplatin administered every two weeks as preoperative therapy for stage II or III breast cancer: NCCTG Study N0338 Roy, Vivek , Pockaj, Barbara A. , Allred, Jacob B. , Apsey, Heidi ... - - Am. J. Clin. Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0338
CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) Rugo, H. S. , Barry, W. T. , Moreno-Aspitia, A. , Lyss, A. P. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40502 , NCCTG-N063H
Long-term follow-up (fu) of (Alliance) CALGB 40502/NCCTG N063H: a randomized phase iii trial of weekly paclitaxel (p) compared to weekly nanoparticle albumin bound nab-paclitaxel (np) or ixabepilone (ix) +/- bevacizumab (b) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) Rugo, Hope S. , Barry, William T. , Moreno-Aspitia, Alvaro ... - SABCS - Cancer Res - 2018 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-40502 , NCCTG-N063H
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) Rugo, Hope S. , Barry, William T. , Moreno-Aspitia, Alvaro ... - - J. Clin. Oncol - 2015 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40502
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Saad, Everardo D , Squifflet, Pierre , Burzykowski, Tomasz ... - - Lancet Oncol. - 2019 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - N9831 , NSABP B-31
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials Saha, Poornima , Regan, Meredith M. , Pagani, Olivia ... - - J. Clin. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Validation of the Preoperative Endocrine Prognostic Index in the ACOSOG (Alliance) Z1031 Neoadjuvant Aromatase Inhibitor Trial Sanati, Souzan , Suman, Vera J. , Goncalves, R. , DeSchryver, K. ... - SABCS - Cancer Res. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Seidman, Andrew D , Berry, Donald , Cirrincione, Constance ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9840
Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Serie, DJ , Crook, JE , Necela, BM , Dockter, TJ , Wang, X , Asmann, YW ... - - Pharmacogenet. Genomics - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact. Shah, Mithun Vinod , Wiktor, Anne E. , Meyer, Reid G. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
A model-based approach to dose optimization of neurotoxic chemotherapy drugs for metastatic breast cancer (MBC) Sharma, Manish , Gray, Elizabeth , Mehrotra, Shailly , Wu, Kehua ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - CALGB-40502
Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101 Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - - J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40101
Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy. Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - SABCS - - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-40101
Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 Shulman, L. , Berry, D. , Cirrincione, C. , Becker, H. , Perez, E. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - C40101
Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance) Shulman, Lawrence N. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-40101
Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance. Sideras, K. , Moreno-Aspitia, A. , Tenglin, R. C. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N1031
North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane Sideras, Kostandinos , Dueck, Amylou C. , Hobday, Timothy J. ... - - Clin. Breast Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Sikov, W. , Berry, D. , Perou, C. , Singh, B. , Cirrincione, C. ... - SABCS - Cancer Res. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40603
Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer Sikov, W. , Perou, C. M. , Golshan, M. , Collyar, D. , Berry, D. A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-40603
Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance) Sikov, William M. , Barry, William T. , Hoadley, Katherine A. ... - SABCS - Cancer Res. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) Sikov, William M. , Berry, Donald A. , Perou, Charles M. ... - - J. Clin. Oncol - 2015 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40603
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance) Sikov, William M , Berry, Donald A , Perou, Charles M , Singh, Baljit ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603
A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072 Simmons, Rache M. , Ballman, Karla V. , Cox, Charles , Carp, Ned ... - - Ann. Surg. Oncol. - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1072
A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results From ACOSOG (Alliance) Z1072 Simmons, Rache , Ballman, Karla , Cox, Charles , Carp, Ned ... - ASBrS - Ann. Surg. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1072
Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831. Soyano, Aixa Elena , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - JCO - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial Sukov, W. R. , Miller, D. V. , Dueck, A. C. , Tenner, K. S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2− invasive breast cancer Suman, Vera Jean , Ellis, Matthew J. ... - - Chin Clin Oncol - 2015 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011106
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Tan, W W , Hillman, D W , Salim, M , Northfelt, D W , Anderson, D M ... - - Ann. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-0332
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial Tan, W. W. , Dueck, A. C. , Flynn, P. , Steen, P. , Anderson, D. ... - - Ann. Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0539
N0539 Phase II Trial of Fulvstrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial. Tan, W. W. , Dueck, A. C. , Flynn, P. , Steen, P. , Anderson, D. ... - SABCS - Cancer Res. - 2009 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0539
Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer. Tan, W. , Allred, J. , Moreno-Aspitia, A. , Northfeld, D. , Ingle, J. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N093B
N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer Tan, W. , Allred, J. , Salim, M. , Flynn, P. , Kugler, J. W. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - Breast - N0337
Phase I study of panobinostat (LBH589) and letrozole in post-menopausal metastatic breast cancer patients Tan, Winston W. , Allred, Jacob B. , Moreno-Aspitia, Alvaro ... - - Clin. Breast Cancer - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-N093B
Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial Tan, Winston W. , Allred, Jacob B. , Salim, Muhammad , Flynn, Patrick ... - - Clin. Breast Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0337
Translational correlates, including outcome for patients (pts) with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) Thome, S. , Hobday, T. , Hillman, D. , Aubry, M. , Lingle, W. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0234
Impact of Adjuvant Trastuzumab on Local-regional Failure Rates in the NCCTG N9831 (Alliance) Study Thorpe, Cameron S. , Vargas, Carlos E. , Dueck, Amylou C. ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Mammographic Breast Density Response to Aromatase Inhibition Vachon, Celine M. , Suman, Vera J. , Brandt, Kathleen R. ... - - Clin. Cancer Res. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-N063I
Receptor Activator of Nuclear Factor Kappa B (RANK) Expression in Primary Breast Cancer Correlates with Recurrence Free Survival and Development of Bone Metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657) Vidula, Neelima , Yau, Christina , Li, Jiali , Esserman, Laura J. ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010 Wilke, Lee G. , Ballman, Karla V. , McCall, Linda M. ... - - Ann Surg Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. Winer, Eric P , Berry, Donald A , Woolf, Susan , Duggan, David ... - - J. Clin. Oncol. - 2004 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9342
Change in mammographic density with metformin use: A companion study to NCIC study MA.32. Wood, Marie E. , Qin, Rui , Le-Petross, Huong T. , Hwang, E Shelley ... - ASCO - J. Clin. Oncol. - 2013 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A211201
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. de Azambuja, Evandro , Ponde, Noam , Procter, Marion , Rastogi, Priya ... - - Breast Cancer Res. Treat. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831
